Bristol-Myers Squibb Co. and Bavarian Nordic formed an agreement providing Bristol-Myers Squibb an exclusive option to license and commercialize Prostvac, Bavarian Nordic’s investigational phase III prostate-specific antigen targeting immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, in a deal worth up to $975 million.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe